NCT05010330|Unknown
Identify Prognostic Biomarkers of Lung Cancer
Multi-omics Combined With Clinical Data Analysis to Identify Prognostic Biomarkers of Lung Cancer
Loading search results
Multi-omics Combined With Clinical Data Analysis to Identify Prognostic Biomarkers of Lung Cancer
Sponsor study identifier
observational
500
1 country
1
Study Start
July 1, 2020
Actual (reported)Primary Completion
September 20, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
September 30, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Multi-omics and Clinical Data Analysis is potential to predict the prognosis of lung cancer patients.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
September 30, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 1, 2020
Actual (reported)July 27, 2021
Actual (reported)August 18, 2021
Actual (reported)September 20, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
September 30, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Identify some prognostic biomarkers in lung cancer.
1. Our study will identify some biomarkers that can predict the prognosis of lung cancer patients. 2. Our study will construct a new risk score model that provide a candidate model for prognostic evaluation of lung cancer. 3. Our research will provide insights for precision immunotherapy of lung cancer by exploring the differences in clinical characteristics, tumor mutation burden, and tumor immune cell infiltration between different risk score groups.
1 week
healthy people
patients diagnosed with lung cancer
Individuals aged between 18 and 80 years old. Patients with diagnosis of lung cancer or healthy controls without any history of tumor will be eligible for our enrollment.
Renji Hospital, Shanghai Jiaotong University school of medicine
Shanghai, 021, China
Zhang Y, Yang M, Ng DM, Haleem M, Yi T, Hu S, Zhu H, Zhao G, Liao Q. Multi-omics Data Analyses Construct TME and Identify the Immune-Related Prognosis Signatures in Human LUAD. Mol Ther Nucleic Acids. 2020 Sep 4;21:860-873. doi: 10.1016/j.omtn.2020.07.024. Epub 2020 Jul 23.
In this study ,we planned to collect plasm from the two cohorts, and lung cancer tissues and para-carcinoma tissue from lung cancer patients who had a tumor excision
Huijing Huang
RenJi Hospital
First Submitted
July 27, 2021
First Posted
August 18, 2021
Study Start
July 1, 2020
Actual (reported)Primary Completion
September 20, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Breath Analysis in Early Stage Lung Cancer Using Infrared Spectroscopy
Contact the study team to confirm eligibility.
Study Completion
September 30, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
August 18, 2021
Record last verified: 2021-08
There is no plan to make individual participant data (IPD) available to other researchers.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: